Nexium Granule, Delayed Release
Product Images NDC 0186-4025

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Nexium (NDC 0186-4025). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Astrazeneca Pharmaceuticals Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (Image 01)

Chemical structure diagram of esomeprazole magnesium trihydrate, the active ingredient in NEXIUM. The diagram shows the molecular arrangement with two connected aromatic rings, sulfur, nitrogen, oxygen atoms, and magnesium ion complexed with three water molecules.*

FDA Label Image

Figure 2 Maintenance Of Healing Rates By Month (study 117) (Image 02)

A line graph showing the percentage of subjects maintained over six months on NEXIUM granules delayed release at 10 mg, 20 mg, and 40 mg strengths compared to placebo. The x-axis represents months, and the y-axis shows the percent maintained, with higher retention for the 40 mg dose over time.*

FDA Label Image

Figure 3 Maintenance Of Healing Rates By Mondy (study 178) (Image 03)

A line graph showing percentage of subjects maintaining a condition over 6 months, comparing NEXIUM delayed release granules at 10 mg, 20 mg, and 40 mg doses versus placebo. The vertical axis represents percent maintained from 0 to 100%, and the horizontal axis represents time in months from 0 to 6. Higher doses of NEXIUM maintain a higher percentage over time compared to placebo, which declines substantially.*

FDA Label Image

Figure 4 Percent Of Patients Symptom-free Of Heartburn By Day (study 225) (Image 04)

A line graph showing the percent of patients symptom-free over a 28-day diary period. Three lines compare NEXIUM 40 mg, NEXIUM 20 mg, and placebo groups, indicating changes in symptom-free percentages across days with NEXIUM groups generally higher than placebo.*

FDA Label Image

Figure 5 Percent Of Patients Symptom-free Of Heartburn By Day (study 226) (Image 05)

A line graph showing the percent of patients symptom-free over a 28-day diary period. It compares three groups: NEXIUM 40 mg, NEXIUM 20 mg, and Placebo, with the percent of patients symptom-free plotted on the vertical axis and diary days on the horizontal axis.*

FDA Label Image

Nexium 20 mg (30 Delayed-Release Capsules)

Label for Nexium (esomeprazole magnesium) 20 mg delayed-release capsules, containing 30 capsules per package. The label includes the NDC code 0186-5020-31 and indicates the product is Rx only. Manufactured by AstraZeneca Pharmaceuticals LP, with a note to dispense the accompanying medication guide to each patient.*

FDA Label Image

Nexium 40 mg (30 Delayed-Release Capsules)

Nexium 40 mg delayed-release capsules packaging label displaying the proprietary and generic name (esomeprazole magnesium). The label indicates a quantity of 30 capsules, prescription only, with a note to dispense the accompanying medication guide. Manufactured by AstraZeneca Pharmaceuticals LP, with branding and logo visible.*

FDA Label Image

Image 08

Nexium 2.5 mg esomeprazole magnesium delayed-release oral suspension carton label. The label indicates 30 single-dose child-resistant packets per carton for prescription use only. Manufacturer is AstraZeneca Pharmaceuticals LP. The label highlights the 2.5 mg strength prominently in an orange circle.*

FDA Label Image

Image 09

Nexium 5 mg oral suspension carton label for delayed-release granules. The label lists the active ingredient as esomeprazole magnesium and states the package contains 30 single-dose packets. It features the AstraZeneca logo and includes the NDC number 0186-4050-01.*

FDA Label Image

Nexium 2.5 mg (30 Single Dose Granular Packet, for Delayed-Release Oral Suspension)

Nexium 10 mg delayed-release oral suspension packaging label for esomeprazole magnesium by AstraZeneca Pharmaceuticals LP. The carton contains 30 child-resistant single dose packets. The label displays the proprietary name, strength, dosage form, and indicates the inclusion of a medication guide.*

FDA Label Image

Nexium 5 mg (30 Single Dose Granular Packet, for Delayed-Release Oral Suspension)

Nexium 20 mg delayed-release oral suspension carton label featuring esomeprazole magnesium as the active ingredient. The label states each carton contains 30 single-dose, child-resistant packets. The label includes the AstraZeneca Pharmaceuticals LP logo and a barcode.*

FDA Label Image

Nexium 10 mg (30 Single Dose Granular Packet, for Delayed-Release Oral Suspension)

NEXIUM 40 mg delayed-release oral suspension granules packaging label. The label indicates the product contains 30 single-dose, child-resistant packets. It is manufactured by AstraZeneca Pharmaceuticals LP and includes dosing and dispensing instructions along with the NDC code 0186-4040-01.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.